



Rotherham Place Board – Wednesday 16 November 2022

2022-23 Quarter 1 Medicines Management Report


Lead Executive	Wendy Allott, Chief Finance Officer – Rotherham, NHS SY ICB
Lead Officer	Stuart Lakin, Head of Medicines Management

Purpose
To update Place Board on the Quarter 1 medicines management position.
Background
<p>The Medicines Management Team (MMT) monitors and advises on all aspects of prescribing that is attributed to Rotherham Place.</p> <p>The attached report details</p> <ul style="list-style-type: none"> • The financial performance against budget. • The quality initiatives that are being implemented.
Analysis of key issues and of risks
See attached report.
Patient, Public and Stakeholder Involvement
Not applicable.
Financial Implications
<p>Prescribing is the second largest area of expenditure for Place and the South Yorkshire Integrated Care Board (ICB). Whilst the financial risk of this area of expenditure resides with the ICB, we have little influence over the “prescribers” whose actions impact on prescribing expenditure.</p> <p>Prescribing costs are influenced by a wide range of factors that are often outside of the individual clinician’s control such as:</p> <ul style="list-style-type: none"> • National guidance (NICE etc) • New clinical evidence • Drug shortages – resulting in patients having to prescribing less cost-effective alternatives • Drugs not available at drug tariff price (NHS contract price) <p>Drugs are global commodities and supply chains into the UK are international. The ever-increasing number of drug shortages/supply problems and the inability to obtain drugs at drug tariff prices, will all impact on prescribing costs.</p> <p>The MMT engages with prescribers to get them to accept ownership of the financial impact of their prescribing, even though increased prescribing costs will have little direct impact on the clinician.</p>
Approval history
Not applicable.
Recommendations
Rotherham Place Board is asked to note the Quarter 1 position in the attached report.


2022-23 Quarter 1 (APR-JUN 2022) Medicine Management Report



	2020/21 YTD	2021/22 YTD	2022/23 YTD
April	£3,880,989	£3,772,777	£3,628,925
May	£7,412,329	£7,371,885	£7,460,230
June	£11,284,028	£11,226,367	£11,202,204
July	£15,093,314	£15,007,964	£14,892,333
August	£18,706,302	£18,580,590	£18,881,996
September	£22,591,359	£22,553,824	
October	£26,635,180	£26,273,600	
November	£30,388,524	£30,091,453	
December	£34,236,016	£34,055,504	
January	£37,912,226	£37,599,604	
February	£41,405,019	£40,947,725	
March	£45,409,242	£44,837,507	



	2020/21 YTD	2021/22 YTD	2022/23 YTD
April	531,501	520,442	519,544
May	1,023,309	1,014,582	1,064,858
June	1,548,218	1,544,586	1,597,095
July	2,066,890	2,080,122	2,112,661
August	2,557,390	2,583,347	2,665,889
September	3,084,277	3,137,298	
October	3,642,478	3,662,701	
November	4,158,725	4,200,676	
December	4,692,658	4,760,799	
January	5,196,633	5,283,228	
February	5,676,039	5,724,407	
March	6,228,050	6,278,292	



Cost growth at -0.57% is below the average for England and Y&H this is despite the strong item growth which at 3.30% is slightly above that for England and Y&H.

NCSO (no cheaper stock obtainable is beginning to cause issues and this may impact on the finance forecast going forward.

NCSO has contributed £207,535 to the Q1 cost growth (Cost growth is -ve but would be -ve by a further £207,535) £121,419 (58.9%) of the NCSO situation is caused by four drugs namely ibandronic acid, sulfasalazine, lercanidipine and alendronic acid it is not possible to do a simple switch from these drugs patients would have to have a therapeutic reviewed.

Strong cost growth is seen with diabetes drugs 11.16% (+£441,631 12 months) this reflects the increase in diabetes seen post pandemic (+13% in patient numbers 18,000 Rotherham patients have diabetes.) There is also strong increase in the

prescribing of continuous and intermittent glucose monitoring systems (+62% both cost and items + £164,886) this is in response to NICE guidance. Oral anticoagulant prescribing continues to increase Item growth = 5.80 % cost growth 11.24% = £392,284 12-month cost growth. There has been a strong increase in HRT prescribing nationally prescriptions increase by 42% Rotherham is slightly above the national trend (item - +52% Cost + 70% £164,886 12 months). The ongoing shortages of HRT products is making cost effective prescribing difficult.


Conversely significant cost reductions are being seen for PPI, non-opioid analgesic, and SSRI antidepressants as NCSO issues have resolved.

Practice budget performance

Please see attachment

QIPP Savings

A cost effective QIPP programme has been launched to run over the year this has achieved savings of £143,641 over 2022/23.

Title	Estimated efficiency	YTD saving	Supporting info & comments
Changes of Combined Oral Contraceptives	£12K	£2,055	Supply issues and extended prescription durations may affect savings.
Edoxaban first line choice	£100K	£12,656	Supporting practices to use most cost effective DOAC
Co-codamol formulation change	£30K	£10,180	Continued savings from work undertaken in 21/22 period
Iron Sulphate reduction		To commence	Work to commence  Iron supplements QIPP.docx
Computerised decision support tool	£200K	£118,750	Active management of decision support tool
Title	Estimated efficiency	YTD saving	Supporting info & comments
Use of Vencarm	£22K	Ongoing	Change to more cost effective Venlafaxine brand
Buprenorphine patch choice	£40K	To commence	Potential for use of cheaper brand subject to patient feedback

QIPP Quality

Medicines Safety Dashboard has been established.

This tracks the prescribing of 14 high risk drugs to ensure that essential monitoring is being undertaken. The dashboard will be shared with practices every quarter.

Antidepressant prescribing

Rotherham has one of the highest rates of antidepressant use in Y&H following an extensive patient engagement exercise and NICE guidance that highlighted the difficulties in stopping antidepressants a pilot scheme was launched to offer patients the opportunity to review their antidepressant use and work with a pharmacist to reduce and stop the medication.

This scheme was launched in the middle of the COVID pandemic and therefore was conducted entirely virtually

In agreement with practices 9,765 patients were considered suitable for a review

The Antidepressant (Deprescribing) Pilot has been running for 12 months and has been live in 23 GP practice. Now in the final round, two practices will go live in Nov 2022 leaving just 3 practices (Crown St, Clifton and Kiveton) unable to partake due to pilot schedule.

There are 24,765 patients in Rotherham being treated with an antidepressant (approximately 10% of the total population)

- Approx. 7k eligible pts have been invited, so far, to self-refer by sms invite to patient leaflet.
- 4881 clicks (70% of sms invites) have been recorded on patient leaflet
- Apart from a small handful (4) all patients that have completed the entire pathway and either successfully stopped their antidepressant or are on a lower dose
- 659 patients have stopped their antidepressant medication
- Zero (0) pts have suffered withdrawal side-effects during the weaning phase
- No practices are reported any issues/workload created as a result of this pilot"

The scheme is funded for a further 12 months and will be extended to incorporate benzodiazepine and anxiolytic medication.

Chronic pain management

The ICS funded CROP (Campaign to Reduce Opioid Prescribing) analysis across the ICB has now concluded. These reports have been sent directly to practices and have demonstrated a modest reduction in high dose opioid prescribing. There has been a decrease in patients over the age of 18 on opiates, a decrease in the percentage of patients on strong opiates, a decrease in the number of males aged 18-50 years old on strong opiates and a decrease in the number of females over 65 prescribed opiate.

We are working with Connect Healthcare on instigating a chronic pain clinic focusing on reduction of chronic opiate usage within the calendar year.

Chronic pain was discussed at a recent meeting with the Rotherham MBC Health Select Committee. Local councillors expressed concern with the ease of access to opioid analgesia and were very supportive of measures to address the management of chronic pain.

Care Home Hydration project

The care home hydration project has been successful in its bid for funding from NHSE (100K)

This will be used to make the project support worker full-time for a period of two years and to relaunch the virtual training package with the input from a creative media company.

AMD treatment pathways

Ophthalmology injections for AMD cost just over £2million each year in Rotherham and activity is increasing by 8%/annum. The first biosimilar (i.e. generic) for ranibizumab became available in October 2022, and TRFT have already started using it.

Rotherham MMT working with the Primary Care Team and TRFT clinicians have maintained the use of ranibizumab as the first line agent for the treatment of AMD. Ranibizumab still accounts for 60% of AMD treatments and the introduction of the biosimilar versions will produce a saving of 78K/month.

Diabetes Treatment Pathways

Pre the COVID pandemic there were 15,939 patients registered with diabetes in Rotherham as of April 2022 there are 18,167 patients an increase of 14%

Rotherham has in recognition of the challenges in managing diabetes started to review its diabetes treatment pathways. Rotherham has traditionally had comparatively high treatment costs\diabetes patients but poor outcomes in blood sugar control as measured by HbA1c.

A Rotherham wide diabetes summit was held in September where a consensus on the way forward was agreed. A diabetes risk stratification tool has been run in 25 of Rotherham's 28 GP practices and is beginning to show results with improvements in patient markers.

PCN diabetes dietetic clinics have been established across all PCN's. These clinics are initially focusing on newly diagnosed diabetes patients with the aim of preventing patients having to commence diabetes medication.


Activity/results to date

263 Patients attended the service to date.

Average HbA1c starting 63mmol/mol

Average HbA1c ~ 3 months post diagnosis 50mmol/mol

63 patients achieved HbA1c in remission range (<48)




PCN Breakdown	HbA1c Pre mmol/mol	HbA1c Post mmol/mol
Matlby Wickersley:	59.8	48.7
Wentworth 1	60.4	44.9
Raven	65.7	51.9
Rotherham Central North	66	51.5
Rother Valley South	61.7	51.1
Health Village Dearne Valley	60	50.6

Weight

Average weight starting 100.1kg

Average weight ~3 months post diagnosis 96.4kg



PCN Breakdown	Weight Pre KG	Weight Post KG
Matlby Wickersley:	100.8	99.5
Wentworth 1	97.9	93.4
Raven	110.4	103.2
Rother Valley South	96.4	93.3
Health Village Dearne Valley	100.8	96.1

These new clinics have received very positive feedback from both practices and patients

In the next phase patients that have been identified in using high doses of insulin (In excess of 100units/day) and still have poor HbA1c control will be invited to participate in a joint DSN/dietitian clinic. To do this the insulin dose of 3350 patients needs to be confirmed, to date the doses of 28% of patients have been confirmed.

Infant Feeding Pathway

(See Appendix 2)

Stuart Lakin
Head of Medicines Management
NHS South Yorkshire (Rotherham)

PCN	Practice	22/23 Yearly Budget	Budget Q1 22/23	Actual Spend Q1 22/23	Q1 22/23 Over/underspend	
					£	%
Health Village / Dearne Valley	Clifton	£1,977,802	£494,451	£518,781	£24,330	4.69
	Market Surgery	£1,908,802	£477,201	£483,568	£6,367	1.32
	St Ann's	£3,201,992	£800,498	£733,350	£-67,148	-9.16
		£7,088,596	£1,772,150	£1,735,699	£-36,451	-2.10
Maltby / Wickersley	Blyth Road	£1,004,599	£251,150	£277,969	£26,819	9.65
	Braithwell Road	£640,349	£160,087	£159,288	£-799	-0.50
	Manor Field	£1,155,161	£288,790	£300,337	£11,547	3.84
	Morthern Road	£1,820,998	£455,250	£477,748	£22,498	4.71
	Wickersley HC	£1,065,028	£266,257	£282,856	£16,599	5.87
	£5,686,135	£1,421,534	£1,498,198	£76,664	5.12	
Raven	Brinsworth	£1,478,011	£369,503	£345,836	£-23,667	-6.84
	Gateway	£1,283,739	£320,935	£317,248	£-3,687	-1.16
	Stag	£1,953,146	£488,287	£514,745	£26,458	5.14
	Thorpe Hesley	£855,815	£213,954	£216,031	£2,077	0.96
	Treeton	£1,033,657	£258,414	£275,218	£16,804	6.11
	£6,604,368	£1,651,093	£1,669,078	£17,985	1.08	
Rother Valley South	Dinnington	£3,471,428	£867,857	£839,416	£-28,441	-3.39
	Kiveton Park	£1,721,101	£430,275	£440,843	£10,568	2.40
	Swallownest	£2,570,239	£642,560	£616,516	£-26,044	-4.22
	Village	£1,306,133	£326,533	£315,765	£-10,768	-3.41
	£9,068,901	£2,267,225	£2,212,540	£-54,685	-2.47	
Rotherham Central North	Broom Lane	£2,409,732	£602,433	£601,161	£-1,272	-0.21
	Greasborough	£625,063	£156,266	£153,068	£-3,198	-2.09
	Greenside	£1,027,468	£256,867	£237,949	£-18,918	-7.95
	Woodstock Bower	£1,912,797	£478,199	£411,300	£-66,899	-16.27
	£5,975,060	£1,493,765	£1,403,478	£-90,287	-6.43	
Wentworth 1	Crown Street	£1,678,177	£419,544	£397,767	£-21,777	-5.47
	High Street	£1,249,893	£312,473	£325,498	£13,025	4.00
	Magna	£2,433,452	£608,363	£549,305	£-59,058	-10.75
	Parkgate	£1,093,321	£273,330	£258,425	£-14,905	-5.77
	Rawmarsh	£580,408	£145,102	£121,411	£-23,691	-19.51
	Shakespeare Road	£762,811	£190,703	£132,512	£-58,191	-43.91
	York Road	£741,574	£185,394	£186,862	£1,468	0.79
	£8,539,636	£2,134,909	£1,971,780	£-163,129	-8.27	
TOTAL		£42,962,696	£10,740,676	£10,490,773	£-249,903	-2.38

Infant feeding Data for April 2021-March 2022

A total of 351 referrals for possible Cows Milk Protein Allergy (CMPA) were received by RNDs between April 2021 – March 2022. This equates to 12.5% of all live registered births in the time frame. Of these 11 (3%) were referred onto the Paediatrician by the Dietitian due to clinical symptoms or non-resolution of symptoms following intervention or if IgE allergy was considered.


In total 157 (45%) of babies referred were confirmed to have/ were treated for CMPA.

188 (54%) treated/confirmed as another infant feeding problem eg Gastroesophageal reflux disease.

3 patients (<1%) were not seen as the parent/carer did not attend/answer the phone.



The number of babies diagnosed with CMPA by the team is 5.6% of all the babies born (Allergy UK state that cows milk allergy is shown to affect up to 7.5% of infants in the first year of life)

	Apr-Jun 21	July - Sept 21	Oct- Dec 21	Jan - Mar 22
Number of GP/HV Referrals	72	86	82	105
Number of live births	665	678	741	713
Percentage referred to infant feeding service	10.8%	12.7%	11%	14.7%
Number seen within 7 days	64 (89%)	79 (91%)	78 (95%)	100 (95%)
Number diagnosed with CMPA	30	48	36	43
Number diagnosed with other infant feeding problem	42	38	46	62
Number referred to Paediatrician	3 (4%)	5 (6%)	2 (2.4%)	1 (0.95%)




This graph above shows the spend for the 2 types of formula used for suspected/confirmed CMPA over time in Rotherham. The spend on amino acid formula has decreased with an increase in the extensively hydrolysed formula. This is a positive outcome of the dietetic intervention as it is preferable to use the extensively hydrolysed formula over the amino acid formula. This is because using the extensively hydrolysed formula does not fully eliminate the cows milk protein which may improve the likelihood of outgrowing the allergy. For the baby the hydrolysed formula tastes better and for the NHS it is lower cost when compared to the amino acid formulas.

The 2 graphs below show the monthly/quarterly diagnosis rates for infants referred to the infant feeding dietetic service for suspected cows milk allergy.



The graph below shows the total spend for specialist infant formula over a 12 month period and also includes information for the other areas in the ICB. The data has been taken from open prescribing for all areas except Rotherham which is taken for the Rotherham prescribing database.



This table shows the number of babies born across the ICB information from MMT at ICB – 03L taken from ONS August 2022 for the year of 2021

	Babies born
Sheffield	5723
Rotherham	2814
Doncaster	3333
Barnsley	2521